From Pseudohemophilia to VWF Biology

How observation, assays, multimers, and molecular biology changed what von Willebrand disease meant

Why this spoke matters

Von Willebrand disease did not enter medicine as a molecule.

It entered as a pattern.

A family bled. Women bled. Children bled. The bleeding looked inherited, but it did not behave like classic hemophilia.

That is the historical lesson.

Before there was a VWF gene, before multimer analysis, before ristocetin assays, before type 2 subtypes, there was bedside observation.

The history of VWD is therefore not just a chronology. It is a lesson in how disease categories are shaped by the tools available to see them.

Each era changed what clinicians thought VWD was: first a familial bleeding tendency, then hereditary pseudohemophilia, then a platelet and vessel-wall disorder, then a plasma factor abnormality, then a platelet-adhesion disorder, then a multimer disorder, then a molecularly heterogeneous condition.

The disease did not simply become better understood.

It became differently understood.

Pattern before mechanism

Erik Adolf von Willebrand’s original description was grounded in clinical observation.

The index patient was Hjördis, a young girl from Föglö in the Åland Islands. She belonged to a large family marked by recurrent bleeding. Several relatives had severe symptoms, and three of her siblings had already died from hemorrhage. Hjördis herself had recurrent epistaxis, gingival bleeding, bruising, and prolonged bleeding after minor trauma. She later died at age 14 during uncontrolled menstrual bleeding.¹

The key features were not molecular. They were relational: bleeding across generations, mucocutaneous rather than deep muscular bleeding, prominent bleeding in females, variable severity within a family, and a pattern distinct from classic hemophilia.

That is why the origin story still matters.

The first act of recognition was not biochemical.

It was phenotypic.

A clinician saw that this was not simply hemophilia under another name. The disorder crossed the categories available at the time. It looked hereditary, but not X-linked. It caused bleeding, but not the same bleeding. It involved families, but it did not follow the expected script.

VWD began as a diagnostic discomfort.

The old categories were not enough.

The first hypothesis: platelets and the vessel wall

Von Willebrand did not know about VWF.

No one did.

But using the tools available in the 1920s, he made a perceptive inference. The most important laboratory abnormality was a prolonged bleeding time. The platelet count was generally not low enough to explain the bleeding. The clotting time was normal. Clot retraction was normal.

This pattern pointed away from classic hemophilia and toward primary hemostasis.

Von Willebrand proposed that the bleeding could be explained by disturbed platelet function together with a more general abnormality of the capillary wall.²

Incomplete, but directionally correct.

Modern VWF biology would eventually show that the missing factor sits at the interface of platelets, endothelium, subendothelial matrix, blood flow, and coagulation.

Von Willebrand did not identify the molecule.

But he identified the problem.

The shadow of hemophilia

For much of early hematology, hemophilia provided the dominant template for inherited bleeding disorders.

That template was powerful. It linked severe bleeding, male inheritance, and deficiency of a plasma coagulation factor.

VWD did not fit cleanly. Its bleeding was often mucosal. Its inheritance could affect women. Its severity varied. Its laboratory profile was unsettled. Its relationship to factor VIII was confusing.

This is why terms such as “hereditary pseudohemophilia” were historically useful, but also limiting. They named the resemblance without explaining the difference.

The disease passed through several identities before becoming VWD. Depending on the dominant hypothesis of the era, it was described as pseudohemophilia, vascular hemophilia, angiohemophilia, hereditary capillary purpura, or Willebrand-Jürgens thrombopathy.³

Each name carried an assumption. Was the problem in the platelet, the vessel wall, the plasma, the coagulation cascade, or some combination of these?

The word “pseudo” placed VWD in hemophilia’s shadow. It suggested imitation rather than independent biology.

But VWD was not false hemophilia.

It was a different window into hemostasis.

When plasma factor biology changed the question

The next major shift came when VWD became linked to plasma factor biology.

By the 1950s, methods for measuring antihemophilic factor, later factor VIII, became available. Investigators found that some patients with the clinical pattern of VWD also had reduced factor VIII activity.

This was puzzling.

The bleeding phenotype looked like a primary hemostatic disorder.

But the laboratory pointed toward a coagulation factor.

In 1957, Inga Marie Nilsson and colleagues revisited the Åland family and confirmed that affected family members shared the same clinical and laboratory pattern seen in other Swedish patients. They proposed that these patients were deficient in a factor distinct from the factor missing in classic hemophilia A.⁴

The question changed.

It was no longer simply:

Why do these families bleed?

It became:

What is the relationship between this disorder, factor VIII, platelets, and the vessel wall?

That question was transformative.

VWD began to occupy an interface position. It was not only a platelet-like bleeding disorder, not only a coagulation-factor disorder, and not simply vascular fragility. It connected all three.

That interface position remains the key to modern reasoning about VWD.

VWF supports platelet adhesion under shear and stabilizes factor VIII in circulation. Once that dual role became visible, the clinical paradox began to make sense. Mucocutaneous bleeding reflected failure of platelet-dependent primary hemostasis. Low factor VIII in some patients reflected failure of VWF carrier function.

One molecule connected two hemostatic systems.

1971: the disease becomes measurable

The early 1970s transformed VWD diagnosis.

In 1971, Zimmerman and colleagues developed an antiserum against highly purified factor VIII preparations and identified a plasma protein then called factor VIII-related antigen. This protein was present in healthy individuals and in patients with hemophilia A, but reduced or absent in many patients with VWD. It later became clear that this antigen was VWF antigen.⁵

Around the same time, Howard and Firkin observed that ristocetin, an antibiotic whose clinical use was limited by platelet-related toxicity, induced platelet agglutination in normal platelet-rich plasma but not in plasma from patients with VWD.⁶

Soon afterward, quantitative ristocetin cofactor assays were developed, allowing investigators to measure the platelet-dependent activity of the missing plasma factor.⁷

This was a turning point.

VWD became measurable in two complementary ways: how much VWF-like protein was present, and how well that protein supported platelet interaction.

The disease could now be separated more clearly from hemophilia A.

It could also be divided into different forms.

The laboratory could now ask not only how much VWF was present, but whether it worked.

Ristocetin and the accidental history of testing

Some of the most important tools in medicine arrive sideways.

Ristocetin was not developed to diagnose VWD. Its clinical use as an antibiotic was limited by thrombocytopenia. Yet that unwanted effect became diagnostically valuable because ristocetin could induce interaction between VWF and platelet GPIbα in vitro.

An antibiotic whose clinical use was limited by platelet-related toxicity became a hemostasis probe.

That historical turn matters because it illustrates how measurement reshapes disease.

Once clinicians could test platelet-dependent VWF activity, VWD became easier to distinguish from disorders of VWF quantity alone. The assay helped move VWD from a quantitative disorder toward a structure-function disorder.

It also introduced new complexity. A low activity result could reflect reduced protein, defective platelet binding, loss of high-molecular-weight multimers, assay behavior, or another mechanism.

Ristocetin also revealed that VWF-platelet interaction could be abnormal in more than one direction. In some patients, later classified as type 2B VWD, VWF binds platelets too avidly. In platelet-type VWD, the abnormality lies not in VWF but in the platelet GPIb receptor. These disorders can look similar unless the laboratory asks the right mechanistic question.⁸

The test clarified the disease while creating new interpretive problems.

That is the recurring historical pattern.

Every new assay makes something visible.

Every new assay also creates a new gray zone.

When structure entered the story

The recognition of VWF multimers changed VWD classification profoundly.

VWF was no longer just a plasma factor with a measurable level. It was a multimeric adhesive protein whose size distribution mattered.

Large multimers were especially important for platelet adhesion under shear. Their absence or dysfunction helped explain why some patients had disproportionately impaired VWF activity despite measurable antigen.

This was a conceptual leap.

VWD could now be understood in structural terms. Some patients had too little VWF. Some had abnormal assembly or loss of high-molecular-weight multimers. Some had excessive platelet binding. Others had impaired platelet binding, impaired collagen binding, impaired factor VIII binding, or accelerated clearance. These were not merely different test patterns. They were different ways for a large adhesive protein to fail.

In 1980, Ruggeri and Zimmerman demonstrated abnormal multimeric structure in different VWD variants, including patterns that helped distinguish what would become type 2A and type 2B VWD.⁹

The multimer era transformed VWD from a disorder defined by quantity into one defined by architecture.

How much protein was present still mattered.

But how that protein was assembled mattered too.

Classification began to reflect mechanism.

Type 1, type 2, and type 3 were not merely labels. They were attempts to map clinical and laboratory patterns onto biological failure modes.

Later, type 2 disease was subdivided into 2A, 2B, 2M, and 2N, reflecting distinct mechanisms: loss of high-molecular-weight multimers, increased platelet binding, impaired platelet-dependent function without loss of multimers, and impaired factor VIII binding.¹⁰

This was real progress.

It allowed clinicians to reason more effectively about diagnosis, prognosis, and therapy.

But it also carried a risk.

Once categories became more precise, they could seem more complete than they were.

The multimer era taught that structure matters.

It did not prove that structure explains everything.

Patients with similar laboratory patterns could bleed differently. Patients within the same subtype could have different clinical trajectories. Some patients sat uneasily between categories. Others changed over time as VWF levels rose with age, pregnancy, inflammation, or other physiologic modifiers.

Structure explained severity better than earlier models had.

But it did not eliminate judgment.

Therapy changed diagnosis

The history of VWD is also a history of treatment.

For decades, treatment options were limited. A major early advance came with plasma fraction I-O, prepared by Blombäck and Blombäck in the 1950s, which could correct both factor VIII and bleeding-time abnormalities in some patients. Cryoprecipitate then made VWF-containing replacement more widely available because it concentrated antihemophilic factor and VWF without the volume burden of plasma.¹¹

Cryoprecipitate was transformative, but it also belonged to the pre-viral-inactivation era. The later viral safety crisis in bleeding disorders changed the meaning of blood products. Replacement therapy was no longer simply a technical solution. It carried questions of risk, trust, and historical memory.

Desmopressin introduced a different therapeutic idea.

In 1977, Mannucci and colleagues brought DDAVP into clinical use for patients with mild hemophilia A and VWD. Instead of replacing VWF, DDAVP released endogenous VWF from endothelial stores.¹²

This changed more than treatment.

It changed diagnosis.

A DDAVP trial became a physiologic test. A response could reveal stored, releasable, functional VWF. A short-lived response could suggest accelerated clearance. A poor response could shape procedural planning. A thrombocytopenic response could raise concern for type 2B disease.

DDAVP turned endothelial biology into a bedside experiment.

Plasma-derived VWF/FVIII concentrates, and later recombinant VWF, made treatment more specific and safer, especially for patients with severe VWD or those unresponsive to DDAVP.¹³

Therapy also made diagnosis more consequential. A label could open access to preventive treatment, procedural planning, and family counseling. But it could also bring lifelong caution, anxiety before procedures, treatment exposure, insurance consequences, and altered self-understanding.

Naming disease became an intervention.

The genomic era and the limits of molecular certainty

Cloning of the VWF gene in 1985 added another layer of visibility.

Investigators could now move from phenotype to genotype, linking variants, domains, inheritance patterns, and laboratory behavior.¹⁴

This clarified many mechanisms, especially in qualitative type 2 variants and severe type 3 disease.

It also revealed the complexity of mild quantitative disease.

Genetic testing clarified many type 2 and type 3 mechanisms, but it did not eliminate diagnostic uncertainty in mild quantitative VWF deficiency, where VWF variants are less consistently found and non-VWF modifiers contribute. Genotype-phenotype correlation is often weak in mild type 1 VWD and low VWF.¹⁵

ABO blood group, clearance biology, endothelial regulation, platelet biology, age, inflammation, pregnancy, anemia, and environmental context all shape the phenotype.

The genomic era did not replace clinical reasoning.

It refined it.

Molecular testing is powerful when it answers a specific question: whether a low FVIII phenotype reflects type 2N VWD rather than mild hemophilia A, whether enhanced platelet interaction reflects type 2B VWD rather than platelet-type VWD, whether severe deficiency has implications for family counseling, or whether a variant explains the observed laboratory pattern.

But genetics does not abolish the boundary problem.

In some patients, especially those with mild quantitative reductions, the central question remains clinical:

Does this person have a bleeding disorder, a risk state, or physiologic variation with coincidental symptoms?

The gene can help.

It cannot always decide.

The boundary problem

Modern VWD diagnosis inherited a century of increasingly powerful tools.

It also inherited the problem those tools created.

VWF level is not a binary trait. It is continuously distributed across the population, modified by blood group, age, inflammation, pregnancy, stress, hormones, and other genetic and environmental influences. Bleeding symptoms are also common in the general population, especially heavy menstrual bleeding and easy bruising.

This is why the low VWF range is so difficult.

The 30–50 IU/dL range is not merely a laboratory interval. It is the historical residue of a continuous trait being forced into categorical disease language.¹⁶

For some patients, the category helps. It explains a lifelong bleeding pattern, guides procedural management, supports family counseling, and prevents dismissal of symptoms.

For others, the category may overstate what the laboratory value means.

This is the modern version of the old historical problem.

The question is still not simply:

What is the value?

It is:

What does the value mean in this person?

What the history teaches clinicians now

The history of VWD explains why modern clinicians should be cautious with certainty.

A patient with mucocutaneous bleeding and borderline VWF levels lives inside a century of evolving categories.

A patient with low VWF and minimal bleeding reminds us that laboratory abnormality is not the same as disease burden.

A patient whose VWF normalizes with age reminds us that biology changes while labels persist.

A patient with a qualitative defect reminds us that amount and function are not the same.

A patient with low FVIII reminds us that VWF is also a carrier protein.

A patient with gastrointestinal bleeding and loss of high-molecular-weight multimers reminds us that VWF also belongs to vascular biology, shear, and angiodysplasia.

These are not just diagnostic puzzles.

They are historical residues.

The old questions remain inside the new tests.

Clinical synthesis

The history of von Willebrand disease is a history of changing visibility.

Clinical observation identified the pattern. Bleeding time placed the disorder in the world of platelets and vessels. Factor VIII biology complicated the story. VWF antigen testing made the missing protein visible. Ristocetin made platelet-dependent function measurable. Multimer analysis made structure visible. DDAVP response made endogenous reserve testable. Genetics made variants visible.

At each stage, VWD became clearer.

At each stage, it also became more complex.

That is the central lesson.

VWD is not a disease that moved from ignorance to certainty. It moved from one useful model to another.

The best clinicians inherit all of these models without worshipping any one of them.

They know that observation still matters.

They know that assays matter.

They know that structure matters.

They know that genes matter.

And they know that none of these, alone, is the patient.